Company / Operating Cash Flow
Zenas BioPharma, Inc. Operating Cash Flow History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$172.3M
FY2025
5-year range
-$172.3M / -$30.5M
FY2023-FY2025
Trend
-464.5%
vs FY2024
Sector context
#161 of 216
Health Care
What the data says
Operating Cash Flow changed -464% YoY in FY2025, a notable deviation from the 2-year average annual change of -232%.
Based on SEC 10-K filings.
-$172M in FY2025.
Declined from -$31M to -$172M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 216This company -$172.3M Sector average $658.7M
▼
-126.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 464.5% year-over-year.
- Ranks #161 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$172.3M | -464.5% |
| FY2024 | -$30.5M | +0.0% |
| FY2023 | -$30.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026